Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Accounts Payables: 2017-2024

Historic Accounts Payables for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $18.0 million.

  • Arcus Biosciences' Accounts Payables rose 223.08% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.0 million, marking a year-over-year increase of 223.08%. This contributed to the annual value of $18.0 million for FY2024, which is 5.88% up from last year.
  • Arcus Biosciences' Accounts Payables amounted to $18.0 million in FY2024, which was up 5.88% from $17.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Accounts Payables registered a high of $20.0 million during FY2022, and its lowest value of $10.0 million during FY2021.
  • Over the past 3 years, Arcus Biosciences' median Accounts Payables value was $18.0 million (recorded in 2024), while the average stood at $18.3 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 233.38% in 2020, then plummeted by 36.23% in 2021.
  • Yearly analysis of 5 years shows Arcus Biosciences' Accounts Payables stood at $15.7 million in 2020, then tumbled by 36.23% to $10.0 million in 2021, then soared by 100.00% to $20.0 million in 2022, then declined by 15.00% to $17.0 million in 2023, then climbed by 5.88% to $18.0 million in 2024.